Literature DB >> 24757459

Postoperative Cervical Cord Compression Induced by Hydrogel Dural Sealant (DuraSeal®).

Si-Hoon Lee1, Chan-Woo Park1, Sang-Gu Lee1, Woo-Kyung Kim1.   

Abstract

Cerebrospinal fluid (CSF) leakage is a potential complication of cranial and spinal surgery. Postoperative CSF leakage can induce delayed healing, wound infection and meningitis. DuraSeal® (Covidien, Waltham, MA, USA) is a synthetic product which has been increasingly used to facilitate watertight repair of dural defects after cranial and spinal surgery. Despite some advantages of Duraseal®, the authors report a patient who developed cord compression following the use of DuraSeal® in cervical spine surgery in which the expansion of the DuraSeal® was believed to be the causative factor.

Entities:  

Keywords:  CSF leakage; DuraSeal®; Dural sealant

Year:  2013        PMID: 24757459      PMCID: PMC3941731          DOI: 10.14245/kjs.2013.10.1.44

Source DB:  PubMed          Journal:  Korean J Spine        ISSN: 1738-2262


INTRODUCTION

Cerebrospinal fluid (CSF) leakage is a potential complication of cranial and spinal surgery11). Postoperative CSF leakage can induce delayed healing, wound infection and meningitis5,7.11). DuraSeal® (Covidien, Waltham, MA, USA) is a synthetic product which has been increasingly used to facilitate watertight repair of dural defects after cranial and spinal surgery. The DuraSeal® has been demonstrated to be both safe and effective in clinical studies2,4,7,10) and was approved in 2005 by the Food and Drug Administration (FDA). The authors report a patient who developed cord compression following the use of DuraSeal® in cervical spine surgery in which the expansion of the DuraSeal® was believed to be the causative factor.

CASE REPORT

A 59-year-old man presented to the outpatient department with a 2-year history of progressive leg numbness. MRI (Magnetic resonance image) had shown intradural mass broad-based on the left side of the dura that compresses the cord severely, displacing it to the right posterior aspect at C7 level (Fig. 1). Opening the lamina and dura at C7 level, the mass removal was performed. The mass was totally removed and the histopathologic findings of frozen biopsy were consistent with those of a meningioma. When repairing dura, DuraSeal® was applied to dural surface that was incompletely approximated with sutures. Eight hours after surgery, the patient developed left-side weakness to motor grade I. A MRI scan was urgently performed, which demonstrated a large extradural mass which was causing severe cord compression at the level of tumor removal (Fig. 2). The patient underwent an emergency wound exploration. On reoperating wound, a thick layer of gelatinous material consistent with DuraSeal® was initially encountered. The layer of hydrogel compressed the dural sac severely. The hydrogel layer was excised. Also the minimal amount of surgicel was removed, which was separate and not interfering with the DuraSeal®. After surgery the patient is showing slightly improvement with his power increasing to motor grade II.
Fig. 1

Pre-operative T1-weighted, post contrast sagittal (A) and axial (B) magnetic resonance images demonstrating an enhanced an intradural mass from the level of C7.

Fig. 2

Postoperative MRI cervical spine. T2 TSE sagittal (A) and gradient echo axial (C7 level) (B). A large extradural mass, which was causing cord compression at the level of tumor removal, is demonstrated with high T2 signal. The material was found to represent a swollen Duraseal at surgery.

DISCUSSION

CSF leak is a potential complication after cranial and spinal surgery7,11). Leakage of CSF can lead to delayed healing of surrounding tissues such as skin, muscle, and bone due to its caustic effect11). Other potential complications include meningitis and severe headaches from CSF depletion7,11). The aim therefore once a CSF leak is identified, is to stem the leak. Hydrogel sealant (DuraSeal®) is a synthetic sealant approved by the FDA, which has been increasingly used to facilitate watertight repair of dural defects after cranial and spinal surgery, and has been demonstrated to be both safe and effective in clinical studies2,4,7,10). DuraSeal® is a self-polymerizing agent which rapidly forms a firm, watertight hydrogel layer within several seconds of application over the dural surface. In comparison to fibrin glue, there is "stronger tissue adherence strength and burst strength". The firm layer is robust enough to withstand irrigation and gentle suction maneuvers without threat of dislodgement. These properties are advantageous in affecting a watertight barrier to minimize the risk of CSF leakage8). Boogaarts et al. reported no evidence of postapplication CSF leaks or adverse events in 46 patients who had a spontaneous dural tear treated with DuraSeal®2). Cosgrove et al. reported similar findings with no evidence of postapplication CSF leaks in 95.5% of patients and no adverse events with the use of DuraSeal®4). After these reports, the use of DuraSeal® was extended as an adjunct to suture closure of an iatrogenic dural tear. DuraSeal® is believed to be an ideal sealant for spine procedures because it is a nontoxic bioabsorbable synthetic hydrogel composed of 90% water with similar properties to tissue2,9). However, one of the drawbacks of using DuraSeal® is its potential to swell up to 50% and slow absorption rate. According to the manufacturers (Covidien, Waltham, MA, USA), product application to "confined bony structures where nerves are present is contraindicated." Few adverse events have been reported with the use of DuraSeal®1,3,9,11). A study in dog models has demonstrated that hydrogel shows in vivo expansion, and mass effect within the first 2 weeks, after insertion characterized by computerized tomography (CT) and MRI imaging6,11). The first reported complication of DuraSeal® was reported when used as a dural sealant after a posterior fossa decompression for a Chiari malformation1). A 13-year-old girl developed a worsening quadriparesis after the mass effect of hydrdogel sealant on the cervicomedullary region following foramen magnum decompression. A case of cervical cord compression has also been reported in a patient who underwent a C5-C6 anterior cervical decompression and fusion who sustained a CSF leak when excising the posterior longitudinal ligament with DuraSeal® being used as the primary sealant11). Three hours postoperatively, the patient developed progressive upper and lower extremity motor weakness. During emergent exploration and decompression, the surgeons determined the expanded hydrogel was the cause of the compression. Also a case has been reported of DuraSeal® causing cauda equina compression after a patient underwent a lumbar laminotomy and discectomy complicated by a dural tear9). This patient's dural tear was treated with DuraSeal® and the patient developed symptoms of cauda equina compression 9 days postoperatively. The patient was taken emergently to the operating room and during exploration and decompression, a large amount of blue DuraSeal® was visualized. The volume of DuraSeal® removed was measured as 10mL, which is more than three times the amount used primarily, suggesting considerable hydrogel expansion after implantation. DuraSeal® has now been approved for spinal usage by the FDA. To date, the time profile and radiographic appearances of this dural sealant has previously only been systematically characterized in a dog craniotomy model6,8). In a dog model, DuraSeal®'s volume expansion was reported to peak between day 3 and 2 weeks after implantation6,9). To avoid such a complication, we would recommend judicious application of the DuraSeal® with thin-layer application to the defective area only. We would also caution against applying DuraSeal® in a manners such that it extends over and beyond the bone edges bordering the dural surface after bony decompression.

CONCLUSION

Our case demonstrates the use of DuraSeal® over a site of a dural repair is associated with the risk of developing postoperative cord compression as a result of swelling of the DuraSeal®. DuraSeal® tendency to expand is documented both in the instructions for its use and published case reports, and this is also confirmed by our experience. A very thin layer of DuraSeal® should be delivered over the site of dural repair and the possibility of postoperative expansion of it should be recognized by the surgeon.
  11 in total

1.  Study of dural suture watertightness: an in vitro comparison of different sealants.

Authors:  Dorian Chauvet; Viet Tran; Gurkan Mutlu; Bernard George; Jean-Marc Allain
Journal:  Acta Neurochir (Wien)       Date:  2011-10-12       Impact factor: 2.216

2.  Cauda equina syndrome after a TLIF resulting from postoperative expansion of a hydrogel dural sealant.

Authors:  Brian J Neuman; Kristen Radcliff; Jeffery Rihn
Journal:  Clin Orthop Relat Res       Date:  2012-06       Impact factor: 4.176

3.  Polyethylene glycol hydrogel spinal sealant (DuraSeal Spinal Sealant) as an adjunct to sutured dural repair in the spine: results of a prospective, multicenter, randomized controlled study.

Authors:  Kee D Kim; Neill M Wright
Journal:  Spine (Phila Pa 1976)       Date:  2011-11-01       Impact factor: 3.468

4.  DuraSeal magnetic resonance and computed tomography imaging: evaluation in a canine craniotomy model.

Authors:  Daniel F Kacher; Kai Frerichs; Jeffrey Pettit; Patrick K Campbell; Tim Meunch; Alexander M Norbash
Journal:  Neurosurgery       Date:  2006-02       Impact factor: 4.654

5.  Postoperative cervical cord compression induced by hydrogel (DuraSeal): a possible complication.

Authors:  Dushan Thavarajah; Patricia De Lacy; Rahim Hussain; Robert M Redfern
Journal:  Spine (Phila Pa 1976)       Date:  2010-01-01       Impact factor: 3.468

6.  A multicenter, single-blind, prospective randomized trial to evaluate the safety of a polyethylene glycol hydrogel (Duraseal Dural Sealant System) as a dural sealant in cranial surgery.

Authors:  Joshua W Osbun; Richard G Ellenbogen; Randall M Chesnut; Lawrence S Chin; Patrick J Connolly; G Rees Cosgrove; Johnny B Delashaw; John G Golfinos; Jeremy D W Greenlee; Stephen J Haines; Jack Jallo; J Paul Muizelaar; Anil Nanda; Mark Shaffrey; Mitesh V Shah; John M Tew; Harry R van Loveren; Martin E Weinand; Jonathan A White; James E Wilberger
Journal:  World Neurosurg       Date:  2011-12-10       Impact factor: 2.104

7.  DuraSeal-hematoma: concealed hematoma causing spinal cord compression.

Authors:  Gabriel Lee; Cheng Kiang Lee; Michael Bynevelt
Journal:  Spine (Phila Pa 1976)       Date:  2010-12-01       Impact factor: 3.468

8.  Use of a novel absorbable hydrogel for augmentation of dural repair: results of a preliminary clinical study.

Authors:  Jeroen D Boogaarts; J André Grotenhuis; Ronald H M A Bartels; Tjemme Beems
Journal:  Neurosurgery       Date:  2005-07       Impact factor: 4.654

9.  Safety and efficacy of a novel polyethylene glycol hydrogel sealant for watertight dural repair.

Authors:  G Rees Cosgrove; Johnny B Delashaw; J Andre Grotenhuis; John M Tew; Harry Van Loveren; Robert F Spetzler; Troy Payner; Gail Rosseau; Mark E Shaffrey; L Nelson Hopkins; Richard Byrne; Alex Norbash
Journal:  J Neurosurg       Date:  2007-01       Impact factor: 5.115

10.  Cauda equina compression by hydrogel dural sealant after a laminotomy and discectomy: case report.

Authors:  Mike Mulder; J Crosier; R Dunn
Journal:  Spine (Phila Pa 1976)       Date:  2009-02-15       Impact factor: 3.468

View more
  10 in total

Review 1.  Hydrogels for Tissue Engineering: Addressing Key Design Needs Toward Clinical Translation.

Authors:  Fei Xu; Chloe Dawson; Makenzie Lamb; Eva Mueller; Evan Stefanek; Mohsen Akbari; Todd Hoare
Journal:  Front Bioeng Biotechnol       Date:  2022-05-05

2.  Degradable and Removable Tough Adhesive Hydrogels.

Authors:  Benjamin R Freedman; Oktay Uzun; Nadja M Maldonado Luna; Anna Rock; Charles Clifford; Emily Stoler; Gabrielle Östlund-Sholars; Christopher Johnson; David J Mooney
Journal:  Adv Mater       Date:  2021-03-24       Impact factor: 30.849

3.  Tissuepatch is biocompatible and seals iatrogenic membrane defects in a rabbit model.

Authors:  Alexander C Engels; Luc Joyeux; Johannes Van der Merwe; Julio Jimenez; Savitree Pranpanus; David W Barrett; Che Connon; Tina T Chowdhury; Anna L David; Jan Deprest
Journal:  Prenat Diagn       Date:  2017-12-11       Impact factor: 3.242

4.  Percutaneous Epidural Hydrogel Sealant for the Treatment of Spontaneous Intracranial Hypotension: A Case Report of Chronic Thoracic Neuralgia and Technical Lessons Learned.

Authors:  Michael G Hillegass; Samuel F Luebbert; Maureen F McClenahan
Journal:  Case Rep Anesthesiol       Date:  2018-07-03

5.  DuraSeal Exact Is a Safe Adjunctive Treatment for Durotomy in Spine: Postapproval Study.

Authors:  Kee D Kim; Dinesh Ramanathan; Jason Highsmith; William Lavelle; Peter Gerszten; Fernando Vale; Neill Wright
Journal:  Global Spine J       Date:  2018-08-13

6.  Failure Pressures of Dural Repairs in a Porcine Ex Vivo Model: Novel Use of Titanium Clips Versus Tissue Glue.

Authors:  Kevin Chorath; Mason Krysinski; Leonid Bunegin; Jacob Majors; Erik Kent Weitzel; Kevin Christopher McMains; Philip G Chen
Journal:  Allergy Rhinol (Providence)       Date:  2019-09-30

7.  Histopathological Effects of Tissue Adhesives on Experimental Peripheral Nerve Transection Model in Rats.

Authors:  Idiris Altun; Harun Çıralık
Journal:  J Korean Neurosurg Soc       Date:  2015-12-31

8.  Transcutaneous Drainage of Gel-Like Substance after Application of Hydrogel Dural Sealant: Report of Two Cases.

Authors:  Homayoun Siman; Fernando Techy
Journal:  Global Spine J       Date:  2015-04-23

9.  The Use Fibrin Sealant after Spinal Intradural Tumor Surgery: Is It Necessary?

Authors:  Young Il Won; Chi Heon Kim; Chun Kee Chung; Tae-Ahn Jahng; Sung Bae Park
Journal:  Korean J Spine       Date:  2016-03-31

10.  Safety and Efficacy of a Novel, Self-Adhering Dural Substitute in a Canine Supratentorial Durotomy Model.

Authors:  Kevin M Lewis; Jenifer Sweet; Scott T Wilson; Serge Rousselle; Heinz Gulle; Bernhard Baumgartner
Journal:  Neurosurgery       Date:  2018-03-01       Impact factor: 4.654

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.